Russia slashes spending on cancer drugs amid skyrocketing prices: Report

Fierce Pharma ------- Russia has long been considered a prime market for Western biopharma companies in search of new sources of growth. And companies ranging from Pfizer to AstraZeneca have been clamoring to comply with President Vladimir Putin’s demand that they ally with local producers and establish manufacturing plants in Russia. But now Russia is pushing back on an issue that has raised concerns around the world: cancer drug prices. In 2016, spending on cancer treatments fell in about half of the 85 regions of Russia, according to statistics quoted by The Moscow Times. At least two regions cut their annual spending on oncology drugs by nearly 50%. Analysts blamed rising drug prices. To learn more click on the picture below to read the article.